Trial Profile
A phase I study investigating the effect of plerixafor plus pegfilgrastim in patients with multiple myeloma or lymphoproliferative disease and having poor or adequate mobilization of progenitor and hematopoietic stem cell
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2016
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Pegfilgrastim
- Indications Stem cell mobilisation
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 12 Jan 2016 New trial record